Maternal Cannabis Use Linked to Adverse Pregnancy Outcomes
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 12, 2023 -- Maternal cannabis use is associated with adverse pregnancy outcomes known to be related to placental dysfunction, according to a study published in the Dec. 12 issue of the Journal of the American Medical Association.
Torri D. Metz, M.D., from the University of Utah Health in Salt Lake City, and colleagues examined the association between maternal cannabis use and adverse pregnancy outcomes known to be related to placental function in an ancillary analysis of nulliparous individuals treated at eight U.S. medical centers. Participants were recruited from 2010 through 2013; 9,257 were eligible for the analysis.
The researchers found that 610 participants (6.6 percent) had cannabis use: 32.4 and 67.6 percent had exposure only during the first trimester and ongoing exposure beyond the first trimester, respectively. In the propensity score-weighted analyses after adjustment for sociodemographic characteristics, body mass index, medical comorbidities, and active nicotine use ascertained via urine cotinine assays, cannabis exposure was associated with the primary composite outcome: small-for-gestational-age birth, medically indicated preterm birth, stillbirth, or hypertensive disorders of pregnancy (25.9 versus 17.4 percent; adjusted relative risk, 1.29). Cannabis use during the first trimester only was not associated with the primary composite outcome, but ongoing cannabis use was associated with the primary composite outcome (adjusted relative risk, 1.32) in a three-category cannabis exposure model.
"Cannabis use is not safe," coauthor Robert M. Silver, M.D., also from the University of Utah Health, said in a statement. "It increases the risk of pregnancy complications. If possible, you shouldn't use cannabis during pregnancy."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
USPSTF Recommends Screening for Domestic Violence in Pregnant, Postpartum Women
TUESDAY, Oct. 29, 2024 -- The U.S. Preventive Services Task Force recommends screening for intimate partner violence (IPV) in pregnant and postpartum women and women of...
Coffee Intake During Pregnancy Not Linked to Neurodevelopmental Issues
FRIDAY, Oct. 25, 2024 -- Maternal coffee consumption during pregnancy does not likely cause neurodevelopmental difficulties (NDs) in offspring, according to a study published...
Insurance-Related Disparities Seen in Prenatal Diagnosis of Congenital Heart Disease
TUESDAY, Oct. 8, 2024 -- Second-trimester ultrasound receipt mediates a considerable portion of the association between public insurance and prenatal diagnosis of congenital heart...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.